Observational studyBMC nephrology2025
Hemoglobin stability impact on healthcare resource utilization and costs among dialysis-dependent patients with anemia of end-stage kidney disease.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations between erythropoietin resistance and iron metabolism markers in patients undergoing extended-hours and conventional hemodialysis.Clinical and experimental nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of hemoglobin stability on healthcare resource utilization (HCRU) and costs in dialysis-dependent patients with anemia of end-stage kidney disease (ESKD) was evaluated.
methodsThis retrospective, observational study used Optum's de-identified Market Clarity Data (Optum
resultsOf 2,279 eligible patients, 37.1%, 44.1%, and 18.8% had mean hemoglobin levels below, within, and above the target range, respectively, and 78.2% had low TiR. Patients with hemoglobin levels within the target range had a significant cost reduction of $6,201 in red blood cell (RBC) transfusions, and significantly lower incidence of RBC transfusions (46%) and inpatient visits (20%) compared to those below the target range. Mean hemoglobin level within versus above the target range was associated with a significantly higher incidence rate of inpatient visits (14%) and annual costs ($1,958) for RBC transfusions. Patients with high versus low TiR had significantly lower incidence rate of RBC transfusion visits (43%) and inpatient visits (19%), and a significant total healthcare cost reduction of $33,921.
conclusionsIncreasing hemoglobin levels to within the target range, and having a higher TiR, was associated with positive impacts on RBC transfusion frequency, HCRU, and costs among dialysis-dependent patients with anemia of ESKD. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.